Biotech Funding Steady: Investors Eye Late-Stage Assets
Biotech sees stable funding as 2024 venture capital and IPOs rise. Investors focus on late-stage assets amid economic challenges.
- Latest
- Trending
Biotech sees stable funding as 2024 venture capital and IPOs rise. Investors focus on late-stage assets amid economic challenges.
California's AI bill, SB 1047, amended to ease tech fears, balancing innovation with safety. Key changes detailed.
Senator Schumer expresses optimism for bipartisan crypto regulation by year-end 2023.
Companies must adapt as U.S. advances biotech bill restricting Chinese suppliers.
The EU's AI Act enforces strict AI regulations, impacting tech giants with challenges and opportunities in innovation.
Ethereum rebounds amid legal clarity, Russia’s crypto law, aiming for $3,000. Positive trader sentiment boosts ETH prospects.
Senior White House officials met with crypto leaders to discuss industry concerns but made no firm commitments.
EU's Digital Resilience Act mandates stricter IT oversight for banks and tech providers, targeting incident prevention by 2025.
AI firms challenge California bill mandating safety tests to prevent catastrophic harm, fearing impact on innovation.
"Trump's Bitcoin stockpile plan sparks debate; proposals include massive reserves, impacting market dynamics and presidential campaigns."
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.